ミネソタ州における急性骨髄性白血病の臨床試験
ミネソタ州内の拠点で、急性骨髄性白血病に関する27件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- 他48件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
被験者募集中第1相
21歳以下 · 全性別 · 2026/09/23更新 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 他9件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Rochester MN-MAYOMN, Rochester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07008638HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/14更新 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
75歳以下 · 全性別 · 2026/07/06更新 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
60歳以下 · 全性別 · 2026/06/25更新 · NCT03314974A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT03017820Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
- Mark Juckett, MD, Minneapolis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT07591649MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
被験者募集中第2相
2歳〜75歳 · 全性別 · 2026/04/16更新 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT05732103Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
- University of Minnesota/Masonic Cancer Center, Minneapolis
被験者募集中観察研究
25歳以下 · 全性別 · 2026/04/08更新 · NCT05014165MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
被験者募集中第2相
60歳以下 · 全性別 · 2026/04/06更新 · NCT05735717Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Rochester, Rochester
被験者募集中観察研究
18歳以上 · 全性別 · 2026/04/01更新 · NCT06279572A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Mayo Clinic, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/09更新 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Mayo Clinic, Rochester
被験者募集中健康なボランティア歓迎
18歳〜120歳 · 全性別 · 2025/07/25更新 · NCT05237258ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。